| Biomarker ID | 1907 |
| PMID | 30401717 |
| Year | 2019 |
| Biomarker | ANO7; NSA2; BOK; PDE8B; CECR6; PER3; CNNM1; PPP1R7; CNTNAP3; SCAMP1; COX15; SEMA4G; DMGDH; SLC7A8; DUSP1; TMEM18; EPHA7; TRIM8; FAM20C; TSLP; FOXC1; WDR41; ZNF658; GABRG3; GLB1L3; GLOD4; KCNMB1; LOC100128239; LOXL4; MTERFD2; NCAM1; NDN; |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Agressive PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Primary Prostate Cancer Vs Metastatic Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | 491 patients with primary Prostate cancer and 1 with metastatic prostate cancer was used from the TCGA cohort. Results were validated on GEO cohort: GSE21034. Results shown here are for TCGA cohort |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | RNA-Seq |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |